1. Design and implement experiments for the formulation and characterization of polymeric, liposomal, lipid and other nanoparticles for in vivo drug delivery.
2. Lead and participate in the assessment and development of early-stage nanoparticle formulation development activities, including targeted therapies.
3. Must have hands-on experience with HPLC, UPLC equipment and methods.
4. Must have hands-on experience with plate-based assays.
5. Must have experience in development of methods to analyze and characterize drug product formulations, components, and functionality.
6. Experience and technical proficiency with HPLC and other methods for analysis and quantification of small molecules, nucleic acids, proteins, lipids, and polymers is preferred.
7. Experience with cell-based assays a plus.
8. Previous experience and technical proficiency in the physical characterization of nanoparticles, including particle sizing is a plus.
9. Familiarity with lab-scale nanoparticle preparation techniques, including microfluidics technology, is a plus.
10. Experience with automated liquid handlers is a plus.
11. Experience with field flow fractionation and multi-angle light scattering a plus.
12. Strong interpersonal, communication, collaboration, and problem-solving skills.
13. Ability to document work and proven record of scientific technical writing
Requirements
- Laboratory: 1 year (Preferred)
- HPLC: 1 year (Preferred)
- plate-based assays: 1 year (Preferred)
- lipid nanoparticle: 1 year (Preferred)
Skills Required
- Degree in Chemistry, Biochemistry, Pharmaceutical Sciences, Chemical Engineering, or related disciplines
- Laboratory experience
- HPLC experience
- Experience with plate-based assays
- Experience with lipid nanoparticle
What We Do
Allen Spolden specializes in clinical research operations management and provides tailored workforce solutions for clinical research organizations, pharmaceutical, biotech, and healthcare sectors. They offer services in clinical research, data management, regulatory affairs, and talent acquisition.
